Economics · November 16, 2026 · Moderate impact
Summit Therapeutics shares tumble after FDA declines to approve its lung-cancer drug
The FDA declined to approve one of biotech's most closely watched cancer drugs, a lung-cancer treatment from Summit Therapeutics. The regulator told the company that the drug needs to prove it can help people live longer. The company's stock fell sharply on the news.
A rejection tied to proof of extended survival sets a high bar for the drug's path to market and hits a closely watched biotech stock.